Argent BioPharma Expands Pipeline with Promising Drug CimetrA®

About this update from Argent Biopharma Ltd

PERTH, Australia , March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients. Key Findings: CEO Roby Zomer  stated: "These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development." With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil ®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil ® is making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma's commitment to addressing global health challenges. For further information, please contact: Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 [email protected] Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 [email protected] View original content: https://www.prnewswire.com/news-releases/argent-biopharma-expands-pipeline-with-promising-drug-cimetra-302402507.html SOURCE Argent BioPharma Ltd.

View stock analysis, news, and events for Argent Biopharma Ltd